David Thomas Evans - 12 Jan 2026 Form 4 Insider Report for Cardlytics, Inc. (CDLX)

Role: Chief Financial Officer
Issuer symbol: CDLX
Report date: 12 Jan 2026
Net transaction value: $0
Form type: 4
Accepted by SEC: 16 Jan 2026, 16:46:07 UTC
Next filing: 19 May 2026
SEC filing: View on sec.gov
Reporting owner signature: /s/ Nick Lynton, Attorney-in-Fact

Key filing fact

David Thomas Evans filed Form 4 for Cardlytics, Inc. (CDLX) on 16 Jan 2026.

Key facts

This page summarizes David Thomas Evans's Form 4 filing for Cardlytics, Inc. (CDLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jan 2026, 16:46.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001730451 Primary reporting owner

Evans David Thomas

Relationship: Chief Financial Officer
Address: C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 4100, ATLANTA
Signature: /s/ Nick Lynton, Attorney-in-Fact
Signature date: 16 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDLX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +1,000,000
Change %
Price: $0.000000
Shares after: 1,000,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

50% of the shares underlying the RSU award will vest on February 1, 2027, with the remaining 50% vesting in equal amounts quarterly over a one-year period through February 1, 2028, provided that the Reporting Person remains employed by the Issuer on such vesting dates.